BAMS
LRMR icon

Bellevue Asset Management (Switzerland)’s Larimar Therapeutics LRMR Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8,333
Closed -$3.19M – 130
2015
Q3 		$3.19M Buy
+8,333
New +$3.76M 0.52% 59

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s LRMR Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 8,333 shares — an estimated $3.19M sold.

Bellevue Asset Management (Switzerland) first reported a position in LRMR in Q3 2015 and held it in 1 quarter. The position peaked at $3.19M in Q3 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Bellevue Asset Management (Switzerland) reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Bellevue Asset Management (Switzerland) sold 8,333 Larimar Therapeutics shares in Q4 2015, an estimated $3.19M.
  • Bellevue Asset Management (Switzerland) first reported a position in Larimar Therapeutics in Q3 2015 and held it in 1 quarter.
  • Bellevue Asset Management (Switzerland)'s Larimar Therapeutics position peaked at $3.19M in Q3 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.